Why the study?
What are the rates of baseline and ongoing monitoring of cardiovascular and metabolic risk factors in patients prescribed atypical antipsychotics?
What are the rates of baseline and ongoing monitoring of cardiovascular and metabolic risk factors in patients prescribed atypical antipsychotics?
Monitoring of cardiovascular and metabolic risk factors in patients on atypical antipsychotics is currently low in routine clinical practice and requires improvement.
Answers are grounded in this paper and cite their sources.
Suboptimal monitoring signals care gaps in antipsychotic prescribing; cross-sectional data leaves open whether interventions improve long-term outcomes.
OBJECTIVES: To examine baseline testing and ongoing monitoring of cardiovascular and other risk factors in individuals prescribed atypical antipsychotic medications. METHODS: We derived a list of baseline and ongoing monitoring tests from the literature (Weight, BMI, blood pressure, U&E, LFTs, glucose, HbA1C, FBC, TFTs, prolactin, lipids & ECG) and then reviewed a random sample of 80 records of patients prescribed atypical antipsychotics and currently attending an Irish public catchment area service, for evidence of testing. RESULTS: Levels of testing for baseline tests ranged from 45% for blood pressure to 0% for BMI. Levels of ongoing monitoring tests ranged from 42.5% for U&E to 0% for BMI. Patients admitted to hospital were much more likely to have had testing. CONCLUSIONS: The need for baseline and ongoing monitoring of certain tests in patients prescribed atypical antipsychotics is increasingly accepted. Levels of such testing are currently quite low and need to increase.
No takes yet. Share an insight, caveat, or question.
Feeney et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: